PDEX

Pro-Dex is a genuinely high-quality small-cap: it designs and manufactures autoclavable battery-powered surgical drivers and shavers for the orthopedic, thoracic and CMF markets, and the fundamentals show it. FY2025 revenue of $66.6M (+23.7%) caps five straight years of durable top-line growth ($38M→$42M→$46M→$54M→$67M), operating income rose 49% to $10.7M (16.1% operating margin), and ROE is a strong 24.5%. The balance sheet is not stretched — liabilities/equity of just 0.67x, equity up 18.7% to $36.6M, retained earnings up 33%. At $61.33 the stock trades at 23x FY diluted EPS of $2.67 and 3.0x sales; against ~24% revenue growth and mid-20s returns on equity, that is a fair-to-reasonable price, not an expensive one, and management is a disciplined capital allocator (never paid a dividend, $3.5M of buybacks, share count down 2.9%).

The reason this is a hold rather than a buy is earnings quality and liquidity. Net income tripled to $8.98M (+322%), but that headline growth is flattered by a depressed FY2024 base ($2.13M) — FY2023 already earned $7.07M, so the true multi-year trajectory is lumpy, not a clean 300% step-up. More importantly, operating cash flow was NEGATIVE $1.68M despite record accounting earnings, and cash fell 84% to just $419K while long-term debt grew 29% to $15.4M. Current assets jumped 29%, so the cash is largely tied up in a working-capital build (inventory/receivables) funded by the credit line — common for a fast-growing manufacturer, but it leaves almost no buffer. A company that earns $9M yet burns cash and holds $419K is one you own, not one you add to aggressively.